CEO of Concert Pharmaceuticals Speaks on how the Company is Applying its Proprietary DCE (Deuterated Chemical Energy) Platform to Modify Drug Molecules with Healthcare Global
CEO of Concert Pharmaceuticals speaks on the company's expansive pipeline of products by applying its proprietary DCE (deuterated chemical entity) Platform to modify specific properties of validated drug molecules.
SAN DIEGO, CA, June 30, 2011
In a report in Healthcare Digital, Roger Tung, CEO of Concert Pharmaceuticals speaks on the company's expansive pipeline of products by applying its proprietary DCE (deuterated chemical entity) Platform to modify specific properties of validated drug molecules. Concert Pharmaceuticals is using its deuterium chemistry technology to create new and different patentable drugs for the treatment of HIV, pain/spasticity, epilepsy, oncology, diabetic nephropathy, among other ailments.To date, Concert Pharmaceuticals has more than 90 patent applications for new drug candidates tackling a broad range of therapeutic areas. In addition to a strong management team and Board of Directors, Concert Pharmaceuticals prides its success on the support of venture capitalists and other investors who have supported its research and development and pipeline advancement. The company has raised more than $110 million since its inception.
While Concert Pharmaceuticals currently conducts research and development on several programs, taking an approach that is unique in the industry. "The approach we take is unusual in the fact that we start out with compounds that have very well understood pharmacological activity and are often known to be well tolerated," says Roger Tung, CEO of Concert Pharmaceuticals. "We carry out these processes with an atom called deuterium, which is a relative of hydrogen that, in favorable cases, can change the metabolism of compounds and improve their suitability for the treatment of disease. Our two lead drug candidates treat chronic kidney disease, particularly diabetic nephropathy, and HIV infection."
Read the article here.
About Concert Pharmaceuticals:
Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.
Concert applies its proprietary DCE Platform (deuterated chemical entity platform) to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense.
About Healthcare Global
Healthcare Global is a pioneering digital media site for Healthcare professionals and executives responsible for all aspects of managing this environment. Healthcare Global covers solutions that enable global healthcare executives to improve the way they manage their operations. Healthcare Digital is the industry-dedicated arm of the White Digital Media Group. Founded in 2007 by entrepreneur Glen White, White Digital Media retains a diversified portfolio of websites, magazines, daily news feeds and weekly e-newsletters that leverage technology to innovatively deliver high-quality content, analytical data, and industry news.
Healthcare Global is headquartered in San Diego, California, with additional offices in Boston, Toronto, Mumbai and Norwich, England. For more information, contact 760-827-7800 or visit http://www.healthcare-digital.com.